The clearances for the conduct of the country’s eight month-long Ivermectin clinical trial are expected to be released within this month, the Department of Science and Technology (DOST) said Friday, Jan. 7.
Ivermectin pills (Photo courtesy of IndiaMart via PNA) “All clearances are anticipated t
The Department of Science and Technology (DOST) has explained why the country’s eight month-long clinical trial seeking to assess the efficacy, safety, and effect on viral clearance of anti-parasitic drug Ivermectin in asymptomatic and mild coronavirus disease (COVID-19) patients confined in isolati
(PGH Facebook Page/Manila Bulletin File Photo)
DOST-MIRDC Executive Director Robert O. Dizon disclosed this at the sidelines of DOST Secretary Fortunato “Boy” T. de la Peña’s weekly report on Friday, May 7.
“Nung April nabuo na ang medical team na magsasagawa ng trial na ito. Maayos na rin ang susundin nila na safety protocol. Hinihintay na lang ngayon na bumaba ang kaso ng COVID (coronavirus disease) kasi gagawin natin ang trial sa PGH (Last April, the medical team that will conduct this trial was formed. The safety protocol was also developed. We are just waiting for the cases of COVID to come down because we will conduct the trial at PGH),” he said.
OstreaVent I and II (Screenshot from DOSTv Facebook Page)
DOST Secretary Fortunato “Boy” T. de la Peña said OstreaVent II was developed by the agency’s Metals Industry Research and Development Center (MIRDC) in partnership with the Breath of Life Foundation Inc.
“It can be used by both infant and adult; it is both pressure- and volume-controlled; it measures tidal volume, and it has bacterial and viral filters,” he said during his weekly report on Friday.
He noted that the clinical trial for the OstreaVent II “will start as soon.”
OstreaVent II used the technology of its predecessor, the OstreaVent I, which is for infant use only, he said.
(FACEBOOK/MANILA BULLETIN)
During his weekly report on Friday, April 9, DOST Secretary Fortunato “Boy” T. de la Peña said OstreaVent II, which was developed by the DOST-Metals Industry Research and Development Center (MIRDC) in collaboration with Breath of Life Foundation. has already secured the major requirements to proceed with clinical trials.
He said the modified OstreaVent got the certification from third company Medical Equipment Healthcare Group, Inc. (MedEquip), which conducted the safety testing and performance verification.
Since August 2020, OstreaVent II has undergone a series of performance and calibration tests by MedEquip.
De la Peña said aside from MedEquip certification, OstreaVent II also got “ethics approval” from the University of the Philippines Manila Research Ethics Board (UPMREB) as well as the Certificate of Medical Device Listing (CMDL) from the Food and Drug Administration (FDA).